Co-Authors
This is a "connection" page, showing publications co-authored by Makoto Ishii and Yoshifumi Uwamino.
Connection Strength
0.634
-
Accuracy and stability of saliva as a sample for reverse transcription PCR detection of SARS-CoV-2. J Clin Pathol. 2021 01; 74(1):67-68.
Score: 0.226
-
The real-time reverse transcription-polymerase chain reaction threshold cycle values for severe acute respiratory syndrome coronavirus 2 predict the prognosis of coronavirus disease 2019 pneumonia. Respir Investig. 2021 May; 59(3):360-363.
Score: 0.058
-
Incomplete humoral response including neutralizing antibodies in asymptomatic to mild COVID-19 patients in Japan. Virology. 2021 03; 555:35-43.
Score: 0.058
-
Acute onset olfactory/taste disorders are associated with a high viral burden in mild or asymptomatic SARS-CoV-2 infections. Int J Infect Dis. 2020 Oct; 99:19-22.
Score: 0.056
-
Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease. Open Forum Infect Dis. 2019 Apr; 6(4):ofz108.
Score: 0.051
-
Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease: A cross-sectional study. Respir Med. 2018 05; 138:1-6.
Score: 0.047
-
Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease. BMC Pulm Med. 2017 Dec 13; 17(1):198.
Score: 0.047
-
Clinical characteristics of pulmonary Mycobacterium lentiflavum disease in adult patients. Int J Infect Dis. 2018 Feb; 67:65-69.
Score: 0.047
-
The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases. BMC Infect Dis. 2017 08 09; 17(1):558.
Score: 0.046